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Background: Sildenafil, a phosphodiestase type 5 inhibitor, was approved in 2005 for the
treatment of pulmonary arterial hypertension (PAH) in adults and is commonly used off-
label for pediatric patients. Little is known, however, about sildenafil’s side effects in this
population.
Methods: Single institution, longitudinal survey-based study performed in an outpatient
pediatric cardiology clinic. Pediatric patients on sildenafil [alone or in combination with other
pulmonary hypertension (PH) therapies] completed questionnaires regarding frequency of
vascular, gastrointestinal, neurologic, and hematologic side effects.
Results: Between January 2011 and May 2014, 66 pediatric patients with PH on sildenafil
filled out 214 surveys, 32 patients (96 surveys) on monotherapy, and 43 patients (118 sur-
veys) on sildenafil plus an endothelin receptor antagonist (ERA) (bosentan or ambrisentan)
and/or a prostacyclin (epoprostenol or treprostinil). Overall, 30% of respondents identified
at least one side effect. For all patients on sildenafil, incidence of side effects by system
was 37% gastrointestinal, 35% vascular, and 22% neurologic. For patients on sildenafil
monotherapy, incidence of side effects by system was 24% gastrointestinal, 21% vascu-
lar, and 18% neurologic compared to patients on combination therapy who reported an
incidence of 48% gastrointestinal, 45% vascular, and 25% neurologic.
Conclusion: Incidence of vascular, gastrointestinal, and neurologic side effect in pedi-
atric patients on sildenafil therapy for PAH was 30%. Side effects were more common
in patients on combination therapy with an ERA and/or prostacyclin than in patients on
sildenafil monotherapy.
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INTRODUCTION
Sildenafil, a phosphodiesterase type 5 inhibitor, was approved
in 2005 by the Food and Drug Administration (FDA) for the
treatment of adults with pulmonary arterial hypertension (PAH).
According to the package insert, common side effects include
headache, flushing, epistaxis, gastrointestinal distress, and blurred
vision (1–3).
As with other therapies for pulmonary hypertension (PH),
sildenafil is used off-label for treatment of PH in pediatric patients.
The current literature, however, is sparse with respect to side effects
in this population. One previous study in the pediatric popu-
lation reviewed cases reported to the FDA between November
1997 and December 2009 and found 588 pediatric adverse event
reports (257 deaths) for sildenafil, bosentan, and epoprostenol.
The study was limited, however, by lack of patient specifics pro-
vided to the authors by the FDA, and a significant bias in reporting
only the most significant events by the care providers to the
FDA (4).
Given the reported frequency of adverse events in the pedi-
atric population, and the recent FDA warning (http://www.fda.
gov/Drugs/DrugSafety/ucm390876.htm) with regard to the use
of sildenafil in pediatric patients, it becomes important to better
characterize sildenafil’s side effects and provide clinicians with the
data necessary to properly weigh the risks and benefits of its use
(5). In this study, we report the incidence of side effects (some
previously reported in previous trials and/or product labeling, and
others learned through institutional and international community
experience) in pediatric patients on sildenafil monotherapy or in
combination with other pulmonary vasodilators.
MATERIALS AND METHODS
This is a single institution, longitudinal survey-based study per-
formed in an outpatient setting (PH specialty clinic) at a pediatric
tertiary hospital. As part of their routine outpatient visits, pedi-
atric patients with PH/pulmonary vascular disease on sildenafil,
either monotherapy or in combination with other PH therapies,
were given a questionnaire listing common side effects. Patients
received questionnaires each time they were seen in clinic and
asked to indicate whether the side effect occurred “daily/weekly,”
“monthly (or less),” or “never.” Parents filled out paper question-
naires for young children and infants. The Stanford University
Institutional Review Board approved the study. Informed consent
was obtained from the patient’s parents and assent obtained as
appropriate.
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Table 1 | Survey “Demographics.”
Drug # Patients # Surveys PDE-5 ERA Prostacyclin
Sildenafil Bosentan Ambrisentan Epoprostenol Treprostinil
Dual 10 29 x x
6 9 x x
1 2 x x
11 26 x x
Triple 1 1 x x x
6 11 x x x
4 18 x x x
4 22 x x x
PDE-5, phosphodiestase type 5 inhibitor; ERA, endothelin receptor antagonist.
Table 2 | Incidence of reported side effects.
Category Side effect Incidence %
Gastrointestinal Diarrhea 40
Dyspepsia 35
Vascular Flushing 41
Headache 38
Epistaxis 25
Neurologic Myalgia 30
Hyperactivity 26
Pyrexia 24
Insomnia 24
Abnormal vision 9
The side effects were categorized as gastrointestinal (diarrhea,
dyspepsia), vascular (epistaxis, flushing, headache), or neurologic
(abnormal vision, hyperactivity, insomnia, myalgia, pyrexia).
STATISTICS
Fisher’s exact test was performed to compare the incidence of side
effects between patients on sildenafil monotherapy and those on
combination therapy. SPSS (IBM SPSS Statistics, Armonk, NY,
USA) was used for analysis; statistical significance was set at a
p-value of <0.05.
RESULTS
Between January 2011 and May 2014, 66 pediatric patients with
PAH on sildenafil filled out 214 surveys, 32 patients (96 sur-
veys) on monotherapy, and 43 patients (118 surveys) on silde-
nafil plus an endothelin receptor antagonist (ERA) (bosentan
or ambrisentan) and/or a prostacyclin (epoprostenol or tre-
prostinil) (Table 1). Therapies were grouped by pharmacologic
category as numbers were too small for individual drug com-
parisons. Patients who started or stopped combination ther-
apy during the course of the study were included, and com-
pleted surveys based on their regimen at the time of the
clinic visit.
The median patient age was 5.7 years (range 0.2–21.6), and
each patient/parent completed a median of three surveys over
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FIGURE 1 | Side effect frequency on sildenafil monotherapy compared
with sildenafil therapy in combination with endothelin receptor
antagonists and/or prostacyclin.
the course of the study (range 1–13). During the course of
data collection, one patient had an additional therapy added to
sildenafil, eight had adjustments in their combination therapy
(e.g., additional or discontinuation of a third medication), and
one had combination therapy discontinued, leaving the patient on
sildenafil monotherapy.
At least one side effect was reported in 30% of the 214
surveys (13% daily or weekly and 17% monthly or less),
and at least one side effect on one survey in 94% of the
66 patients. Gastrointestinal side effects were most commonly
reported (37% of surveys), followed by vascular (35%) and neu-
rologic (22%) as shown in Table 2. In patients on monother-
apy, 24% reported gastrointestinal side effects, 21% vascular,
and 18% neurologic. Patients on combination therapy had
significantly higher reported side effects: 48% gastrointestinal
(p< 0.001), 45% vascular (p< 0.001), and 25% neurologic
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FIGURE 2 | Side effects on sildenafil monotherapy (A) and combination therapy (B).
(p= 0.001). Figure 1 summarizes the side effect frequency by
system.
The most commonly reported side effects on sildenafil
monotherapy were diarrhea (26%), hyperactivity (25%), and
pyrexia (24%). Dyspepsia and flushing occurred next most com-
monly in monotherapy patients, each occurring in 22% of patients.
On combination therapy, flushing was most commonly reported
(57%), followed by diarrhea (51%), headache (48%), and dyspep-
sia (45%). Monotherapy versus combination therapy side effects
are shown in Figure 2. Patients on combination therapy reported
gastrointestinal and vascular side effects twice as frequently as
patients on monotherapy,while neurologic symptoms were similar
except for myalgias (10% monotherapy vs. 42% combination ther-
apy). The frequency of reported side effects by type of combination
therapy is illustrated in Figure 3.
CONCLUSION
Based on an outpatient questionnaire, 94% of pediatric patients
with PH on sildenafil reported at least one side effect on 30% of all
surveys, 13% occurring frequently (as defined as daily/weekly).
Dosing in all recently initiated patients aligns with current
recommendations: 1 mg/kg TID in patients<10 kg, 10 mg TID in
patients 10–20 kg, and 20 mg TID in patients>20 kg. Historically,
some patients in the 10–20-kg group received 1 mg/kg/dose TID
and were included in this study. No patient in this study received
more than 1 mg/kg/dose TID (3 mg/kg/day), and no patient was
on a dose greater than 20 mg TID.
Side effects were more commonly reported in patients on
combination therapy with an ERA and/or prostacyclin than on
monotherapy, likely due to a synergistic effect as the side effects
reported were the same. The most common side effects both
on monotherapy and combination therapy were flushing, diar-
rhea, dyspepsia, headache, and hyperactivity. Overall, the type of
reported side effects was consistent with previous reports in adult
patients except for the hyperactivity and insomnia, which have not
been previously reported. The incidence of side effects is higher
than previously reported.
In the initial Pfizer sponsored randomized clinical trial in adult
patients, the most common adverse effects were headache, dyspep-
sia, flushing, and epistaxis (1). In the longer follow-up analysis of
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FIGURE 3 | Side effect frequency for different combinations of sildenafil
plus endothelin receptor antagonist (ERA) and/or prostacyclin.
the randomized patients, the adverse effects were consistent with
known side effects: headache, dyspepsia, diarrhea, and blurred
vision (2). In a Cochrane review of 10 randomized studies of all
phosphodiesterase-5 inhibitors approved for treatment of PAH in
adults, headache was the most common side effect in a dose depen-
dent fashion, followed by flushing and myalgias (6). Similarly, in
combination therapy with epoprostenol, reported side effects were
headache, dyspepsia, pain in extremity, and nausea (3).
In an open-label, pilot study of sildenafil use in pediatric
patients with PAH that showed improved 6 minute walk test
time and hemodynamics, there was a low reported incidence of
epistaxis, headache, and flushing (7). The pediatric randomized,
controlled trial prompting the FDA warning also reported a vari-
ety of side effects, most commonly headache occurring in up to
15% of patients, pyrexia, and vomiting in patients all on silde-
nafil monotherapy (8, 9). A recent FDA review of reported adverse
events in pediatric patients on any therapy for PAH revealed a
myriad of adverse events associated with sildenafil therapy not pre-
viously reported in sentinel trials, though it is unclear were related
to underlying disease progression in patients on monotherapy (4).
Although previous studies have suggested dose-related inci-
dence of the aforementioned side effects, the incidence in this
study in patients on a comparatively lower dose was higher than
previously reported. A portion of that increase is likely due to the
number of patients in this study on combination therapy with an
ERA and/or prostacyclin. In addition, the method of self-reporting
via a questionnaire in the outpatient setting likely elicits a higher
response rate than relying on clinician or patient reported formal
adverse events to the FDA. A limitation of this study is that the
date of initiation of sildenafil was not included in the question-
naire and, therefore, the time interval from initiation to occurrence
of symptoms is not specifically known.
Clinicians prescribing sildenafil for pediatric patients with PAH
should inquire about side effects listed here and be prepared
to treat appropriately with supportive medications (i.e., anti-
diarrheal and acid blocker medications for diarrhea and dyspepsia,
respectively). In addition, families should be educated to monitor
for these side effects and report them to their provider in a timely
fashion to avoid discontinuation of medication if side effects can
be appropriately managed.
In conclusion, side effects of sildenafil are common in pedi-
atric PAH patients and more common than previously reported.
In addition, side effects occur more commonly when used in com-
bination with other therapies for PAH. Some, such as hyperactivity
and insomnia, have not been previously described in adult trials
and are important for pediatric clinicians to understand when
considering the balance between “cost” and patient benefit.
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